Swiecicki PL, et al. - Via performing paired phase 2 trials evaluating cetuximab-radiotherapy in two cohorts (a) low-risk HPV+ oropharyngeal carcinoma and (b) cisplatin-ineligible, researchers sought to describe the toxicity and efficacy of cetuximab-radiotherapy. In cohort A, they enrolled 42 patients with a 2-year disease-free survival (DFS) of 81%. In cohort B, enrollment of 21 patients was done prior to closure due to adverse outcomes with a 2-year DFS of 37%. Sixty percent of the patients experienced severe toxicities, 30% needed enteral nutrition. These findings suggest that cetuximab treatment produced poor outcomes among cisplatin-ineligible patients. Rates of severe toxicities were on par with platinum-based regimens implying that cetuximab is not a harmless treatment.